Search Result

Results for "

Axl inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	TAM Receptor (89) Akt (4) Anaplastic lymphoma kinase (ALK) (3) Antibiotic (1) Antibody-Drug Conjugates (ADCs) (2) Apoptosis (19) Autophagy (3) Bacterial (1) c-Fms (4) c-Kit (7) c-Met/HGFR (30) Discoidin Domain Receptor (5) Drug Isomer (1) E1/E2/E3 Enzyme (1) EGFR (1) ERK (2) Fat Mass and Obesity-associated Protein (FTO) (1) FGFR (3) FLT3 (21) Hedgehog (1) HIF/HIF Prolyl-Hydroxylase (3) IGF-1R (4) Isotope-Labeled Compounds (4) JAK (1) MHC (2) MMP (1) p38 MAPK (2) PDGFR (2) PI3K (2) Reference Standards (12) ROS Kinase (3) SARS-CoV (1) Src (1) STAT (1) Survivin (1) TGF-β Receptor (1) Tie (1) Trk Receptor (4) VEGFR (18) VSV (1) YAP (4)
By Research Areas:	Cancer (112) Cardiovascular Disease (4) Endocrinology (3) Infection (4) Inflammation/Immunology (11) Neurological Disease (4)

By Targets:

TAM Receptor (89)

Akt (4)

Anaplastic lymphoma kinase (ALK) (3)

Antibiotic (1)

Antibody-Drug Conjugates (ADCs) (2)

Apoptosis (19)

Autophagy (3)

Bacterial (1)

c-Fms (4)

c-Kit (7)

c-Met/HGFR (30)

Discoidin Domain Receptor (5)

Drug Isomer (1)

E1/E2/E3 Enzyme (1)

EGFR (1)

ERK (2)

Fat Mass and Obesity-associated Protein (FTO) (1)

FGFR (3)

FLT3 (21)

Hedgehog (1)

HIF/HIF Prolyl-Hydroxylase (3)

IGF-1R (4)

Isotope-Labeled Compounds (4)

JAK (1)

MHC (2)

MMP (1)

p38 MAPK (2)

PDGFR (2)

PI3K (2)

Reference Standards (12)

ROS Kinase (3)

SARS-CoV (1)

Src (1)

STAT (1)

Survivin (1)

TGF-β Receptor (1)

Tie (1)

Trk Receptor (4)

VEGFR (18)

VSV (1)

YAP (4)

By Research Areas:

Cancer (112)

Cardiovascular Disease (4)

Endocrinology (3)

Infection (4)

Inflammation/Immunology (11)

Neurological Disease (4)

117

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: TAM Receptor

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-12432

Gilteritinib 40+ Cited Publications ASP2215	FLT3 TAM Receptor	Cancer
Gilteritinib (ASP2215) is a potent and ATP-competitive *FLT3/AXL* inhibitor with IC₅₀s of 0.29 nM/0.73 nM, respectively.

HY-15150

Bemcentinib Maximum Cited Publications 63 Publications Verification R428; BGB324	TAM Receptor	Cancer
Bemcentinib (R428) is a selective and orally active *Axl* inhibitor with an IC₅₀ of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .

HY-15494

Picropodophyllin 25+ Cited Publications Axl1717; Picropodophyllotoxin; PPP	IGF-1R Apoptosis	Endocrinology Cancer
Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC₅₀ of 1 nM.

HY-114166

2-D08 10+ Cited Publications	E1/E2/E3 Enzyme TAM Receptor	Cancer
2-D08 is a cell permeable, mechanistically unique inhibitor of protein SUMOylation. 2-D08 also inhibits *Axl* with an IC₅₀ of 0.49 nM.

HY-14721

Tepotinib 5+ Cited Publications EMD-1214063	c-Met/HGFR Autophagy	Cancer
Tepotinib (EMD-1214063) is an orally active and highly selective, reversible, ATP-competitive c-Met inhibitor with an IC₅₀ of 3 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib inhibits c-Met phosphorylation and induces autophagy. Tepotinib has antitumor effects .

HY-12044

Cabozantinib S-malate 55+ Cited Publications XL184 S-malate; BMS-907351 S-malate	VEGFR Apoptosis	Cancer
Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, *Axl* and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-138696

Zanzalintinib 1 Publications Verification XL092	TAM Receptor c-Met/HGFR VEGFR	Cancer
Zanzalintinib (XL092) is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including MET, VEGFR2, *AXL* and MER, with IC₅₀s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. Zanzalintinib exhibits anti-tumor activity. Zanzalintinib has the potential for kinase-dependent diseases and conditions research .

HY-12963

Dubermatinib 5+ Cited Publications TP-0903	TAM Receptor Apoptosis	Cancer
Dubermatinib (TP-0903) is a potent and selective *Axl* receptor tyrosine kinase inhibitor with an IC₅₀ value of 27 nM.

HY-117596

UNC569 2 Publications Verification	TAM Receptor	Cancer
UNC569 is a potent, reversible, ATP-competitive and orally active Mer kinase inhibitor with an IC₅₀ of 2.9 nM and a K_i of 4.3 nM. UNC569 also inhibits *Axl* and Tyro3 with IC₅₀s of 37 nM and 48 nM, respectively. UNC569 can be used for acute lymphoblastic leukemia (ALL) and atypical teratoid/rhabdoid tumors research

HY-12344

UNC2025 5+ Cited Publications	FLT3	Neurological Disease Cancer
UNC2025 is a potent, ATP-competitive, highly orally active and BBB-permeable Mer/Flt3 inhibitor with IC₅₀ values of 0.74 nM and 0.8 nM, respectively. UNC2025 is >45-fold selectivity for MERTK relative to Axl (IC₅₀= 122 nM; K_i = 13.3 nM). UNC2025 exhibits an excellent PK properties, and can be used for the investigation of acute leukemia .

HY-12432A

Gilteritinib hemifumarate 40+ Cited Publications ASP2215 hemifumarate	FLT3 TAM Receptor	Cancer
Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive *FLT3/AXL* inhibitor with IC₅₀ of 0.29 nM/0.73 nM, respectively.

HY-15797

UNC2250 4 Publications Verification	TAM Receptor	Cancer
UNC2250 is a potent and selective Mer inhibitor with an IC₅₀ of 1.7 nM, about 160- and 60-fold selectivity over the closely related kinases Axl/Tyro3.

HY-12494

LDC1267 5+ Cited Publications	TAM Receptor FLT3	Neurological Disease Cancer
LDC1267 is a *AXL/TAM/FLT3* inhibitor with IC₅₀ values of 42 nM, 130 nM, and 63 nM against AXL, MERTK, and TYRO3, respectively. LDC1267 blocks GAS6-induced AXL phosphorylation and the downstream AKT/ERK1/2 signaling pathway. LDC1267 inhibits cancer cell proliferation, colony formation, and glioblastoma cell invasion, without causing obvious impairment of cytotoxic autophagic flux. LDC1267 exerts a synergistic effect when used in combination with Imatinib (HY-15463) in chronic myeloid leukemia models. LDC1267 can be widely applied in studies related to glioblastoma and chronic myeloid leukemia .

HY-107145A

Ningetinib 1 Publications Verification	TAM Receptor VEGFR c-Met/HGFR	Cancer
Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC₅₀s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and *Axl*, respectively.

HY-100946

CEP-40783 2 Publications Verification RXDX-106	TAM Receptor c-Met/HGFR	Cancer
CEP-40783 is a potent, selective and orally available inhibitor of *AXL* and c-Met with IC₅₀ values of 7 nM and 12 nM, respectively.

HY-114358

Tamnorzatinib 2 Publications Verification ONO-7475	TAM Receptor Trk Receptor	Cancer
Tamnorzatinib (ONO-7475) is a potent, selective, and orally active Axl/Mer inhibitor with IC50 values of 0.7 nM and 1.0 nM, respectively. Tamnorzatinib sensitizes AXL-overexpressing EGFR-mutant NSCLC cells to the EGFR-TKIs, suppresses the emergence and maintenance of tolerant cells. Tamnorzatinib combines with Osimertinib (HY-15772) provides a bright promise for the study of EGFR-mutated non-small cell lung cancer (NSCLC).

HY-13016S

Cabozantinib-d6 XL184-d₆; BMS-907351-d₆	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively .

HY-132200

UNC5293	TAM Receptor Anaplastic lymphoma kinase (ALK) FLT3	Cancer
UNC5293 is a MERTK-selective and potent inhibitor (K_i=190 pM). UNC5293 inhibits MERTK (IC₅₀=0.9 nM) and is more selective over Axl, Tyro3 and Flt3. UNC5293 exhibits excellent mouse PK properties and is used for bone marrow leukemia research .

HY-125510

UNC2541 1 Publications Verification	TAM Receptor	Neurological Disease Inflammation/Immunology
UNC2541 is a potent and Mer tyrosine kinase (MerTK)-specific inhibitor, binds in the MerTK ATP pocket, with an IC₅₀ of 4.4 nM, more selective over Axl, Tyro3 and Flt3. UNC2541 inhibits phosphorylated MerTK (pMerTK; EC₅₀, 510 nM). UNC2541 abolishes the analgesic and anti-inflammatory effects of ozone in vivo and in vitro .

HY-116000

Glumetinib 2 Publications Verification Gumarontinib; SCC244	c-Met/HGFR	Cancer
Glumetinib (SCC244) is a highly selective, orally bioavailable, ATP-competitive c-Met inhibitor with an IC₅₀ of 0.42 nM. Glumetinib has greater than 2400-fold selectivity for c-Met over those 312 kinases evaluated, including the c-Met family member RON and highly homologous kinases Axl, Mer, TyrO3. Antitumor activity .

HY-15798

UNC2881	VSV TAM Receptor	Cardiovascular Disease
UNC2881 is an orally active and specific Mer kinase inhibitor, inhibits steady-state Mer kinase phosphorylation with an IC₅₀ value of 22 nM. UNC2881 shows additional inhibition against *Axl* and Tyro with IC₅₀s of 360 nM and 250 nM, respectively. UNC2881 potently inhibits collagen-induced platelet aggregation, can be used for pathologic thrombosis research .

HY-147218

PF-07265807 ARRY-067	TAM Receptor	Cancer
PF-07265807 (ARRY-067) is a kinase inhibitor with primary targets *AXL, MERTK, and TYRO3. PF-07265807 acts as an immunomodulator that cross-activates CD8 ⁺ T cells by enhancing dendritic cell function. PF-07265807 blocks downstream signal transduction of AXL* and MERTK, and inhibits the proliferation and migration of tumor cells with high expression of these two kinases. PF-07265807 is applicable to research related to advanced or metastatic solid tumors, such as colorectal cancer .

HY-P99463

Batiraxcept 2 Publications Verification AVB-500; AVB-S6-500	TAM Receptor PI3K Akt p38 MAPK	Cancer
Batiraxcept (AVB-500; AVB-S6-500) is a selective, soluble AXL receptor and GAS6 inhibitor that targets the GAS6-AXL signaling axis. Batiraxcept is orally inactive and does not cross the blood-brain barrier. Batiraxcept competitively binds to GAS6 ((K_D <1 nM), preventing its interaction with the AXL receptor tyrosine kinase, thereby inhibiting downstream PI3K/AKT and MAPK signaling pathways, reducing tumor cell glycolysis, angiogenesis, and metastatic potential. Batiraxcept has demonstrated antitumor activity in preclinical models of endometrial, cholangiocarcinoma, and ovarian cancer by inhibiting tumor growth, invasion, and metastasis .

HY-100509

NPS-1034 1 Publications Verification	TAM Receptor c-Met/HGFR Apoptosis	Cancer
NPS-1034 is a dual inhibitor of *AXL* and MET with IC₅₀s of 10.3 and 48 nM, respectively.

HY-12965

S49076 1 Publications Verification	FGFR c-Met/HGFR	Cancer
S49076 is a novel, potent inhibitor of MET, *AXL/MER, and FGFR1/2/3* with IC₅₀ values below 20 nM.

HY-12964

SGI-7079 3 Publications Verification	TAM Receptor	Cancer
SGI-7079 is a selective, ATP-competitive, orally active inhibitor of the receptor tyrosine kinase Axl. SGI-7079 blocks Axl-mediated signaling pathways such as NF-κB activation and MMP-9 expression, thereby inhibiting tumor cell proliferation, migration and invasion. SGI-7079 is mainly used in the research of malignant tumors such as inflammatory breast cancer and bladder cancer, as well as in combination with immunization (used in combination with PD-1 therapy)[1][2][3].

HY-P99161

Tilvestamab BGB149	TAM Receptor	Cancer
Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks *AXL*-mediated cell signaling. Tilvestamab significantly inhibits Gas6-induced *AXL* activation in 786-0-Luc RCC cells and inhibits downstream AKT phosphorylation. Tilvestamab can be used in cancer research, particularly in *AXL* overexpressing renal cell carcinomas .

HY-132893

AZ14145845	TAM Receptor	Cancer
AZ14145845 is a highly selective type I1/2 dual *Mer/Axl* kinase inhibitor with in vivo efficacy.

HY-145622

Mecbotamab vedotin BA3011; CAB-Axl-ADC; CAB-anti-Axl-ADC	Antibody-Drug Conjugates (ADCs) TAM Receptor	Cancer
Mecbotamab vedotin (BA3011) is a pH dependent antibody drug conjugate (ADC) targeting *AXL. Mecbotamab vedotin can significantly inhibit* AXL in DU145 cells and LCLC-103H cells and kills cells. Mecbotamab vedotin can be used for research on cancer such as lung cancer, pancreatic cancer and prostate cancer. The antibody component is Mecbotamab (HY-P9988), and the ADC toxin molecule is Monomethyl auristatin E (MMAE) (HY-15162) .

HY-114356

BPI-9016M	c-Met/HGFR	Cancer
BPI-9016M is a potent, orally active, and selective dual c-Met and *AXL* tyrosine kinases inhibitor. BPI-9016M suppresses tumor cell growth, migration and invasion of lung adenocarcinoma .

HY-114357A

DS-1205b free base	TAM Receptor c-Met/HGFR Trk Receptor	Cancer
DS-1205b free base is a potent and selective inhibitor of AXL kinase, with an IC₅₀ of 1.3 nM. DS-1205b free base also inhibits MER, MET, and TRKA, with IC₅₀s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo .

HY-124066

RU-302	TAM Receptor	Cancer
RU-302 is a pan TAM inhibitor that blocks the interface between the TAM Ig1 ectodomain and the Gas6 Lg domain. RU-302 effectively blocks Gas6-inducible *Axl* receptor activation with a low micromolar IC₅₀in cell assays, and suppresses lung cancer tumor growth .

HY-14721R

Tepotinib (Standard) EMD-1214063 (Standard)	Reference Standards c-Met/HGFR Autophagy	Cancer
Tepotinib (Standard) is the analytical standard of Tepotinib. This product is intended for research and analytical applications. Tepotinib (EMD-1214063) is an orally active and highly selective, reversible, ATP-competitive c-Met inhibitor with an IC₅₀ of 3 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib inhibits c-Met phosphorylation. Tepotinib has antitumor effects .

HY-155310

AF-2112	YAP	Cancer
AF-2112 is a Flufenamic acid-derived TEAD inhibitor hat strongly reduce the expression of CTGF, Cyr61, Axl and NF2.

HY-155309

LM-41	YAP	Cancer
LM-41 is a Flufenamic acid-derived TEAD inhibitor hat strongly reduce the expression of CTGF, Cyr61, Axl and NF2. LM-41 inhibits migration of human MDA-MB-231 breast cancer cells .

HY-176205

Ligritinib AB801	TAM Receptor	Cancer
Ligritinib (AB801) is an orally active *AXL* receptor tyrosine kinase inhibitor. Ligritinib blocks the downstream signaling pathway by inhibiting the kinase activity of AXL. Ligritinib can be used in cancer research, especially in combination with chemotherapy for non-small cell lung cancer (NSCLC) .

HY-12432R

Gilteritinib (Standard) ASP2215 (Standard)	Reference Standards FLT3 TAM Receptor	Cancer
Gilteritinib (Standard) is the analytical standard of Gilteritinib. This product is intended for research and analytical applications. Gilteritinib (ASP2215) is a potent and ATP-competitive *FLT3/AXL* inhibitor with IC₅₀s of 0.29 nM/0.73 nM, respectively.

HY-15494R

Picropodophyllin (Standard) Axl1717 (Standard); Picropodophyllotoxin (Standard); PPP (Standard)	IGF-1R Apoptosis Reference Standards	Endocrinology Cancer
Picropodophyllin (Standard) is the analytical standard of Picropodophyllin. This product is intended for research and analytical applications. Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.

HY-115778

UNC3133	TAM Receptor FLT3	Inflammation/Immunology Cancer
UNC3133 is an orally active, limitedly selective MerTK inhibitor with an IC₅₀ of 3.0 nM. UNC3133 inhibits *Axl, Tyro3* and Flt3 kinases, with IC₅₀ values of 17 nM, 31 nM and 6.8 nM, respectively. UNC3133 is applicable to the research of inflammatory diseases and cancers .

HY-13016S1

Cabozantinib-d4 XL184-d₄; BMS-907351-d₄	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-12344A

UNC2025 hydrochloride 5+ Cited Publications	FLT3	Cancer
UNC2025 hydrochloride is a potent, ATP-competitive, highly orally active and BBB-permeable Mer/Flt3 inhibitor with IC₅₀ values of 0.74 nM and 0.8 nM, respectively. UNC2025 hydrochloride is >45-fold selectivity for MERTK relative to Axl (IC₅₀= 122 nM; K_i = 13.3 nM). UNC2025 hydrochloride exhibits an excellent PK properties, and can be used for the investigation of acute leukemia .

HY-151904

AXL-IN-13	TAM Receptor FLT3 PDGFR	Cancer
AXL-IN-13 is a potent and orally active *AXL* inhibitor (IC₅₀: 1.6 nM, K_d: 0.26 nM). AXL-IN-13 reverses TGF-β1-induced epithelial-mesenchymal transition (EMT), and inhibits cancer cell migration and invasion .

HY-P99921

Enapotamab vedotin HuMax-Axl-ADC	Antibody-Drug Conjugates (ADCs) TAM Receptor	Cancer
Enapotamab vedotin is an AXL-targeted antibody-drug conjugate (ADC) with inhibitory potential against high AXL expressing non-small cell lung cancer (NSCLC). Enapotamab vedotin also exhibits resistant to EGFR inhibitor such as Osimertinib (HY-15772) .

HY-177332

SLC-391	TAM Receptor SARS-CoV Akt	Infection Cancer
SLC-391 is an orally active *AXL* kinase inhibitor with an IC₅₀ of 9.6 nM against *AXL* kinase. SLC-391 inhibits Gas6-induced AXL-dependent phosphorylation of Akt. SLC-391 inhibits SARS-CoV-2 infection, entry and replication in cells. SLC-391 suppresses cancer cell proliferation. SLC-391 inhibits tumor growth in mouse solid tumor xenograft models. SLC-391 can be used for the research of COVID-19, influenza virus infection, triple-negative breast cancer, chronic myeloid leukemia and non-small cell lung cancer .

HY-124502

UNC4203	TAM Receptor FLT3	Cancer
UNC4203 is a potent, orally available and highly selective MERTK inhibitor, with IC₅₀s of 1.2 nM, 140 nM, 42 nM and 90 nM for MERTK, AXL, TYRO3 and FLT3, respectively .

HY-14721A

Tepotinib hydrochloride EMD-1214063 hydrochloride	c-Met/HGFR Autophagy	Cancer
Tepotinib (EMD-1214063) hydrochloride is an orally active and highly selective, reversible, ATP-competitive c-Met inhibitor with an IC₅₀ of 3 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib hydrochloride inhibits c-Met phosphorylation and induces autophagy. Tepotinib hydrochloride has antitumor effects .

HY-153012

Axl/Mer/CSF1R-IN-1	TAM Receptor c-Fms	Cancer
Axl/Mer-IN-1 (Compound 1) is an Axl/Mer receptor tyrosine kinase (Axl/Mer RTK) and CSF1R inhibitor with K_ds of <0.1 μM .

HY-179105

Axl-IN-20	TAM Receptor	Cancer
Axl-IN-20 (Compound w11) is a selective, orally active *AXL* inhibitor, with an IC₅₀ of 5 nM. Axl-IN-20 has antitumor activity against hematological malignancies .

HY-12432S1

Gilteritinib-d8 ASP2215-d₈	FLT3 TAM Receptor	Cancer
Gilteritinib-d₈ is deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.

HY-170668

DDO-02267	Anaplastic lymphoma kinase (ALK) Fat Mass and Obesity-associated Protein (FTO)	Cancer
DDO-02267 is a selective and lysine-targeting covalent inhibitor of ALKBH5, with an IC₅₀ value of 0.49 μM. DDO-02267 increases N ⁶-methyladenosine (m ⁶A) levels and targets the ALKBH5-AXL signaling axis. DDO-02267 can serve as a probe for investigating the biological function of mRNA demethylase .

Cat. No.	Nombre del producto	Type

HY-145622

Mecbotamab vedotin

BA3011; CAB-Axl-ADC; CAB-anti-Axl-ADC

Fluorescent Dyes

Mecbotamab vedotin (BA3011) is a pH dependent antibody drug conjugate (ADC) targeting AXL. Mecbotamab vedotin can significantly inhibit AXL in DU145 cells and LCLC-103H cells and kills cells. Mecbotamab vedotin can be used for research on cancer such as lung cancer, pancreatic cancer and prostate cancer. The antibody component is Mecbotamab (HY-P9988), and the ADC toxin molecule is Monomethyl auristatin E (MMAE) (HY-15162) .

HY-15150G

Bemcentinib (GMP)

R428 (GMP); BGB324 (GMP)

Fluorescent Dyes

Bemcentinib (R428) GMP is Bemcentinib (HY-15150) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy.Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC₅₀ of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .

Cat. No.	Nombre del producto	Type

HY-15150G

Bemcentinib (GMP)

R428 (GMP); BGB324 (GMP)

Biochemical Assay Reagents

Cat. No.	Nombre del producto	Target	Research Area	Image

HY-P99463

Batiraxcept 2 Publications Verification AVB-500; AVB-S6-500	TAM Receptor PI3K Akt p38 MAPK	Cancer
Batiraxcept (AVB-500; AVB-S6-500) is a selective, soluble AXL receptor and GAS6 inhibitor that targets the GAS6-AXL signaling axis. Batiraxcept is orally inactive and does not cross the blood-brain barrier. Batiraxcept competitively binds to GAS6 ((K_D <1 nM), preventing its interaction with the AXL receptor tyrosine kinase, thereby inhibiting downstream PI3K/AKT and MAPK signaling pathways, reducing tumor cell glycolysis, angiogenesis, and metastatic potential. Batiraxcept has demonstrated antitumor activity in preclinical models of endometrial, cholangiocarcinoma, and ovarian cancer by inhibiting tumor growth, invasion, and metastasis .

HY-P99161

Tilvestamab BGB149	TAM Receptor	Cancer
Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks *AXL*-mediated cell signaling. Tilvestamab significantly inhibits Gas6-induced *AXL* activation in 786-0-Luc RCC cells and inhibits downstream AKT phosphorylation. Tilvestamab can be used in cancer research, particularly in *AXL* overexpressing renal cell carcinomas .

HY-P99921

Enapotamab vedotin HuMax-Axl-ADC	Antibody-Drug Conjugates (ADCs) TAM Receptor	Cancer
Enapotamab vedotin is an AXL-targeted antibody-drug conjugate (ADC) with inhibitory potential against high AXL expressing non-small cell lung cancer (NSCLC). Enapotamab vedotin also exhibits resistant to EGFR inhibitor such as Osimertinib (HY-15772) .

HY-P991664

AG01	Src Akt ERK TAM Receptor c-Met/HGFR MMP HIF/HIF Prolyl-Hydroxylase VEGFR	Cancer
AG01 is a monoclonal antibody against progranulin (GP88). AG01 inhibits triple-negative breast cancer (TNBC) cell proliferation and migration, reduces the expression of phosphorylated protein kinases p-Src, p-AKT, and p-ERK, and reduces the expression of oncogenic proteins such as *Axl, c-MET, HIF-1α, and VEGF. AG01 inhibits* tumor growth and Ki67 expression in a TNBC xenograft mouse model. AG01 can be used in the research of TNBC and other cancers .

Cat. No.	Nombre del producto	Category	Target	Chemical Structure

HY-15494

Picropodophyllin 25+ Cited Publications Axl1717; Picropodophyllotoxin; PPP	Classification of Application Fields Lignans Dysosma versipellis (Hance) M. Cheng ex Ying Phenylpropanoids Plants Berberidaceae Disease Research Fields Endocrinology Source Classification	IGF-1R Apoptosis
Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC₅₀ of 1 nM.

HY-15494R

Picropodophyllin (Standard) Axl1717 (Standard); Picropodophyllotoxin (Standard); PPP (Standard)	Structural Classification Lignans Dysosma versipellis (Hance) M. Cheng ex Ying Phenylpropanoids Plants Berberidaceae Source Classification	IGF-1R Apoptosis Reference Standards
Picropodophyllin (Standard) is the analytical standard of Picropodophyllin. This product is intended for research and analytical applications. Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.

HY-N3634

Corylifol C	Leguminosae Phenols Polyphenols Psoralea corylifolia L. Plants Source Classification	EGFR TAM Receptor Tie
Corylifol C is a potent protein kinase inhibitor with IC₅₀ valueS of 8.7, 3.0, 2.1, 6.4, 4.5, 6.2, 2.3, 1.2, 5.1 μg/ml for ARK5, Aurora-A, Aurora-B, AXL, B-RAF-VE, CDK4/CycD1, TIE2, EGF-R, EPHB4, respectively .

HY-N12041

Axl-IN-16	Productos naturales Microorganisms Source Classification	TAM Receptor HIF/HIF Prolyl-Hydroxylase
Axl-IN-16 is a dual inhibitor of *Axl/HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 inhibits* hypoxia-inducible factor activity and receptor tyrosine kinase expression .

Cat. No.	Nombre del producto	Chemical Structure

HY-13016S

Cabozantinib-d6
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively .

HY-13016S1

Cabozantinib-d4
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-12432S1

Gilteritinib-d8
Gilteritinib-d₈ is deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.

HY-15494S1

Picropodophyllin-d6
Picropodophyllin-d₆ (AXL1717-d₆) is deuterium labeled Picropodophyllin. Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.

HY-15494S

Picropodophyllin-d3
Picropodophyllin-d₃ (AXL1717-d₃; Picropodophyllotoxin-d₃; PPP-d₃) is the deuterium labeled Picropodophyllin (HY-15494). Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC₅₀ of 1 nM.

HY-W706452

Cabozantinib-d4 S-malate
Cabozantinib-d₄ (S-malate) (XL184-d₄ (S-malate); BMS-907351-d₄ (S-malate)) is the deuterium labeled Cabozantinib (S-malate) (HY-12044). Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-15150S

Bemcentinib-d8

Bemcentinib-d₈ (R428-d₈) is the deuterium labeled Bemcentinib (HY-15150). Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC₅₀ of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .

Consulta en línea

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Saludo			Country or Region *
Nombre del solicitante *			Nombre de la Organizaciòn *
Department *
Direcciòn del E-mail *			Nombre del producto *
Cat. No.			Requested quantity *
Número de teléfono *
Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent:

Axl inhibitor

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products